Skip to main content
SpringerLink
Log in

Konsequente Abklärung erhöhter Leberwerte

Leberzirrhose und Komplikationen rechtzeitig erkennen

Hepatic cirrhosis: early diagnosis and prevention of complications

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

In der Praxis müssen Sie mit einer steigenden Zahl von Leberzirrhose-Fällen rechnen, nicht nur aufgrund von Alkoholabusus und Virushepatitiden, sondern auch wegen der Zunahme von Adipositas und metabolischem Syndrom. Wie erkennen Sie Betroffene frühzeitig?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Niederau C, Epidemiologie der Leberzirrhose. Hepatitis&more 1/2011-1

  2. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014 May 17;383(9930):1749–61.

    Article  Google Scholar 

  3. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015;149(2):367–78

    Article  Google Scholar 

  4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019 Jan;70(1):172–193. doi: https://doi.org/10.1016/j.jhep.2018.06.024.

    Article  Google Scholar 

  5. Runyon BA et al., Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013 57(4):1651–3.

    Article  Google Scholar 

  6. Gerbes AL, Gülberg V, Sauerbruch T, Wiest R, Appenrodt B, Bahr MJ, Dollinger MM, Rössle M, Schepke M. German S 3-guideline „ascites, spontaneous bacterial peritonitis, hepatorenal syndrome“. Z Gastroenterol. 2011 Jun;49(6):749–79.

    Article  CAS  Google Scholar 

  7. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715–35.

    Article  Google Scholar 

  8. Prakash RK, Kanna S, Mullen KD. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis. Clin Ther. 2013 Sep;35(9):1458–73.

    Article  Google Scholar 

  9. Varakanahalli S, Sharma BC, Srivastava S, Sachdeva S, Dahale AS. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo. Eur J Gastroenterol Hepatol 2018;30(8):951–958

    Article  CAS  Google Scholar 

  10. Bass NM1, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.

    Article  CAS  Google Scholar 

  11. Kalambokis GN et al., Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol. 2012 Jul;10(7):815–8

    Article  CAS  Google Scholar 

  12. Kimer N et al., Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014 Jul;40(2):123–32

    Article  CAS  Google Scholar 

  13. Garcia-Tsao G et al., Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310–335

    Article  Google Scholar 

  14. Sinagra E et al., Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014 Mar;39(6):557–68

    Article  CAS  Google Scholar 

  15. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik und Therapie des hepatozellularen Karzinoms, Langversion 1.0, 2013. AWMF Registrierungsnummer: 032-053OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html

  16. Ge PS, Runyon BA; When should the β-blocker window in cirrhosis close? Gastroenterology. 2014 Jun;146(7):1597–9

    Article  Google Scholar 

  17. Delco F et al., Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529–45.

    Article  CAS  Google Scholar 

  18. Weersink RA et al., Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018 Aug;84(8):1806–1820

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internistisches Klinikum München Süd, Am Isarkanal 36, D-81379, München, Deutschland

    Manfred Gross

Authors
  1. Manfred Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Gross.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gross, M. Leberzirrhose und Komplikationen rechtzeitig erkennen. MMW - Fortschritte der Medizin 161, 48–52 (2019). https://doi.org/10.1007/s15006-019-0408-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-019-0408-9

Keywords

Search

Navigation